Aveo Pharmaceuticals Inc 's

Name: Aveo Pharmaceuticals Inc Comparisons to its Competitors and Market Share - CSIMarket
Creator: CSIMarket.com
License: https://csimarket.com/help/terms-of-use/

Competitiveness

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

AVEO Sales vs. its Competitors Q3 2022

Select the Relationship:

Competition ▼

Select the Category:

Comparison ▼

Competition ▼

Basic Report▼

Revenue Growth Comparisons

Net Income Comparison

Aveo Pharmaceuticals Inc recorded a net loss, as well as most of its competitors.

<< AVEO Stock Performance Comparisons

<< See the full list of AVEO competitors

*Market share is calculated based on total revenue.

News about Aveo Pharmaceuticals Inc Contracts

In-depth Analysis of Tivozanib’s Efficacy in Treating Advanced Renal Cell Carcinoma: Long-term Results from the Phase III TIVO-3 Trial

February 6, 2024
AVEO Oncology recently announced the publication of significant results related to the long-term survival of patients with relapsed or refractory advanced Renal Cell Carcinoma (RCC) who have been treated with Tivozanib. The data, derived from a pivotal Phase III TIVO-3 Trial, provides valuable insights into the potential benefits of this treatment in enhancing the longevity of afflicted individuals, thereby shedding light on novel and promising avenues for RCC treatment.The TIVO-3 trial undertook an assessment of Tivozanib in comparison with sorafenib, a standard-care treatment for advanced RCC, in patients who had shown a lack of response to two or three prior systemic treatments. It was the first study exp...

AVEO's Stock Performance relative to its Competitors

Publicly Traded Peers of Aveo Pharmaceuticals Inc

Protara Therapeutics Inc
Share Performance

+23.03%

One Year

Protara Therapeutics Inc

Profile

Protara Therapeutics Inc is a biopharmaceutical company that focuses on developing and commercializing innovative therapies to address significant unmet medical needs. Their business model revolves around identifying and advancing potential drug candidates that target specific diseases or conditions, conducting extensive research and development to ensure safety and efficacy, and ultimately seeking regulatory approvals and entering the market to make these therapies accessible to patients worldwide. Protara leverages collaborations and partnerships within the healthcare industry to support their research efforts and drive business growth.

More about Protara Therapeutics Inc's Market Share

Market Cap.	Revenues TTM	Net Income TTM
$ 167.061 mill.	$ - mill.	$ -58.294 mill.

Sources: Aveo Pharmaceuticals Inc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on: Tuesday, July 7, 2026 1:49 PM
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Aveo Pharmaceuticals Inc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.